Oncology Business Management

FDA updates from the summer of 2010

FDA updates from Winter 2010

As the number of cancer survivors grows, the disease has emerged as a greater concern for companies anxious to meet the needs of employees and their families while still operating their businesses in an efficient and cost-effective manner.

Forty-six percent of Americans want marijuana to be legalized. Seventy percent of Americans support the legalization of medical marijuana.

Useful Online Resources and Clinical Trials for Oral Cancer

Steadily rising expenses and a proliferation of new drugs are speeding adoption of a host of measures designed to contain drug and treatment outlays more directly

This year in the US, the American Cancer Society estimates that lung cancer will kill more people than breast, prostate, colon, liver, and kidney cancers combined, making it the leading cause of cancer death among Americans.

Additional breaking news from the biotech industry. In this issue: 1) FDA OKs Ikonisys' Bladder Cancer Test 2) Good News From China for Peregrine 3) Introgen Sees Advances on Two Fronts 4) Debiopharm Procures Cancer Therapy from Kirin Brewery

Fast biotech facts and figures. In this issue: 1) Cancer Risk Factors and Mortality 2) Bladder Cancer 3) Testicular Cancer 4) Breast Cancer

The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing the envelope of knowledge and discovery.

The Politics and Policy page provides a concise and timely round-up of key government-related oncology and biotechnology news. Content is focused upon the public sector activities that are most likely to impact the evolving oncology and biotech industries.

Novel immunotherapy approaches to metastatic prostate cancer: Stimulating the immune response ex vivo with autologous antigen presenting cells.

The latest business and financial biotech news. In this issue: 1) Adherex Buys Back GSK%u2019s Rights to Failed Cancer Drug 2) Archemix and Merck Partner on Aptamer-Based Cancer Therapeutics, and more

Successful research into new therapies for cancer requires a ready supply of patients willing to participate in clinical trials, and physicians and other health care professionals who will refer their patients to the appropriate studies.

News items reported in this issue: 1) 186-Gene Signature in Cancer Stem Cells Predicts Recurrence 2) National Prostate Cancer Coalition Commences Clinical Trial Education Program 3) Concomitant High-Dose Radiation Therapy Plus Cetuximab Improves Locoregional Control and Reduces Mortality, with No Increase in Radiation Therapy%u2013Associated Toxicity in Patients with Advanced Squamous-Cell Carcinoma of the Head and Neck, and more

New pancreatic cancer vaccine findings were presented at the 2007 Gastrointestinal Cancers Symposium, held January 19-21 in Orlando, FL.

The fields of oncology and biotechnology are entering a period of rapid growth and transformation. It is an exciting time for physicians, researchers, and allied healthcare professionals. We are honored to be apart of the process.

The treatment of hormone-refractory prostate cancer often represents a therapeutic challenge. As the most common malignancy in men and the second-leading cause of cancer death in the US, the number of patients requiring posthormonal therapy is increasing.

Companies in the news: 1) AVAX and CTCA Collaborating for Cancer Therapies 2) Full Speed Ahead for GPC Biotech's Satraplatin 3) Bristol-Myers Squibb Company / Adnexus Therapeutics: Collaboration for New Oncology Compounds, and more

The Organisation for Economic Co-operation and Development (OECD) (www.oecd.org) %u201Cis a group of 30 member countries sharing a commitment to democratic government and the market economy. Best known for its publications and its statistics, its work covers economic and social issues from macroeconomics, to trade, education, development and science and innovation.%u201D

The Academy delivers the latest news on biotechnology and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing farther into knowledge and discovery.

This month's Fed Focus highlights such topics as Medicare reimbursement for cancer care and NCI budget cuts that affect cancer research.

This month we report on presentations made at the BIO (Biotechnology Industry Organization)CEO & Investor Conference (February 11-14, 2007, New York, NY).